Massachusetts Initiative Looks at Payment Plans for Novartis' SMA Gene Therapy

Many of the new biologic drugs and gene therapies coming on the market have shockingly high prices. Examples include Novartis’ cancer cell therapy, Kymriah, running about $475,000, Gilead’s competitive treatment, Yescarta, priced at $373,000, and Spark Therapeutics’ Luxturna for a hereditary eye disease running about $425,000 per eye.